BACKGROUND: The aim of the study was to evaluate and compare incidence and risk factors of left ventricular dysfunction (LVD) in early breast cancer patients receiving (E+) or not (E-) epirubicin-based adjuvant chemotherapy. PATIENTS AND METHODS: Among eight FASG trials, 3577 assessable patients were analyzed retrospectively: 2553 received epirubicin, 662 received hormonotherapy alone and 362 had no systemic treatment. Chemotherapy was FEC regimen in 86% of cases (fluorouracil, epirubicin, cyclophosphamide). Epirubicin cumulative dose was < 300 mg/m2 in 1040 patients, 300-600 in 1155, > or = 600 in 279, followed by radiotherapy in 96% of cases. RESULTS: Twenty delayed LVD occurred: two in E- patients and 18 in E+ patients. In E+ patients, 14 patients normalized their cardiac function or did not require further investigations, one patient was stabilized with specific treatment, two patients worsened their functions and one died of congestive heart failure. The 7-year risk of LVD was 1.36% (95% CI 0.85-1.87) in E+ patients and 0.21% (95%CI: 0.00-0.52) in E- patients (P = 0.004). Two significant risk factors were identified: age > or = 65 years and body mass index > 27 kg/m2. CONCLUSION: After a long-term follow-up, epirubicin-related LVD risk was acceptable (1.36%) with one toxic death (0.04%). In 78% of cases, LVD were transient or well controlled.
BACKGROUND: The aim of the study was to evaluate and compare incidence and risk factors of left ventricular dysfunction (LVD) in early breast cancerpatients receiving (E+) or not (E-) epirubicin-based adjuvant chemotherapy. PATIENTS AND METHODS: Among eight FASG trials, 3577 assessable patients were analyzed retrospectively: 2553 received epirubicin, 662 received hormonotherapy alone and 362 had no systemic treatment. Chemotherapy was FEC regimen in 86% of cases (fluorouracil, epirubicin, cyclophosphamide). Epirubicin cumulative dose was < 300 mg/m2 in 1040 patients, 300-600 in 1155, > or = 600 in 279, followed by radiotherapy in 96% of cases. RESULTS: Twenty delayed LVD occurred: two in E- patients and 18 in E+ patients. In E+ patients, 14 patients normalized their cardiac function or did not require further investigations, one patient was stabilized with specific treatment, two patients worsened their functions and one died of congestive heart failure. The 7-year risk of LVD was 1.36% (95% CI 0.85-1.87) in E+ patients and 0.21% (95%CI: 0.00-0.52) in E- patients (P = 0.004). Two significant risk factors were identified: age > or = 65 years and body mass index > 27 kg/m2. CONCLUSION: After a long-term follow-up, epirubicin-related LVD risk was acceptable (1.36%) with one toxic death (0.04%). In 78% of cases, LVD were transient or well controlled.
Authors: Ron Shapiro; Daphna Barsuk; Lior Segev; Shani Shimon-Paluch; Haim Berkenstadt; Douglas B Zippel; Moshe Z Papa Journal: Ann R Coll Surg Engl Date: 2010-11-18 Impact factor: 1.891
Authors: José M Serrano; Iria González; Silvia Del Castillo; Javier Muñiz; Luis J Morales; Fernando Moreno; Rosa Jiménez; Carmen Cristóbal; Catherine Graupner; Pedro Talavera; Alejandro Curcio; Paula Martínez; Juan A Guerra; Joaquín J Alonso Journal: Oncologist Date: 2015-07-16
Authors: Chetan Shenoy; Igor Klem; Anna Lisa Crowley; Manesh R Patel; Mark A Winchester; Cynthia Owusu; Gretchen G Kimmick Journal: Oncologist Date: 2011-07-07
Authors: L M Boerman; A J Berendsen; P van der Meer; J H Maduro; M Y Berger; G H de Bock Journal: Support Care Cancer Date: 2014-03-02 Impact factor: 3.603
Authors: James P Carroll; Melinda M Protani; Linda Nguyen; Matthew E Cheng; Mike Fay; Mohamed Saleem; Praga S Pillay; Euan Walpole; Jennifer H Martin Journal: Med Oncol Date: 2014-02-19 Impact factor: 3.064